B-Raf IN 8 is a potent B-Raf inhibitor with an IC50 of 70.65 nM; it exhibits strong antitumor activity against hepatocellular carcinoma (HepG-2), colon cancer (HCT-116), breast cancer (MCF-7), and human prostate cancer (PC-3) cells, with IC50 values of 9.78, 13.78, 18.52, and 29.85 µM, respectively.